Sagimet Biosciences SGMT 深 滬
已收盤 08-07 16:00:00 美东时间
9.06
+0.320
+3.66%
華盛通- 最 高9.09
- 今 開8.91
- 成交量 111.31万股
- 最 低 8.4501
- 昨 收 8.74
- 總市值 5.59亿
- 52周最高 9.46
- 市盈率 靜 --
- 換手率 1.80%
- 52周最低 4.50
- 委 比 -73.01%
- 總股本 6175.18万
- 歷史最高 20.71
- 量 比 0.62
- 振 幅 7.32%
- 歷史最低 1.73
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sagimet updates acne pipeline and funding strategy
Sagimet Biosciences, Inc. Class A ( ($SGMT) ) just unveiled an announcement. On...
07-21 18:28
Sagimet Biosciences Added To Broad-Market Russell 3000 Index And Small-Cap Russell 2000 Index
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has been added to the broad-market Russell 3000® Index and small-cap Russell 2000® Index, effecti...
06-29 19:15
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
Sagimet Biosciences Inc. has been added to the Russell 3000® and Russell 2000® Indexes, effective June 29, 2026. The inclusion reflects the company's progress, including plans to initiate a U.S. Phase 3 clinical trial for denifanstat in moderate to severe acne later this year. CEO David Happel highlighted the potential of denifanstat as the first innovative oral treatment for acne in over 40 years. Sagimet aims to leverage the broader visibility ...
06-29 11:00
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 1% on Thursday. Shares of Legend Biotech Corp (NASDAQ:LEGN) fell sharply in pre-market trading after the company announced the pricing of public offering. Legend Biotech priced a public offering of 7.7 million ADSs at ...
06-18 20:02
Sagimet Biosciences Announces Board Changes and Director Elections
The latest update is out from Sagimet Biosciences, Inc. Class A ( ($SGMT) ). On...
06-13 05:00
Sagimet Biosciences Grants New Performance-Based Executive Equity Awards
An announcement from Sagimet Biosciences, Inc. Class A ( ($SGMT) ) is now avail...
06-04 06:07
UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In Adults
https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-associated-steatohepatitis-mash-in-adults
06-03 23:30
Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased
Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trialPhase 1 data show rapid reductions in cholesterol
05-27 19:15
